The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

(RTTNews) - Arcus Biosciences, Inc. (RCUS) Thursday said that its quemliclustat was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic ...

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A ...

HAYWARD, Calif.& TOKYO---- Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., Ltd. today announced that Taiho exercised its option for quemliclustat, an investigational small molecule CD73 ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer, is expected to be fully enrolled by the ...